AZN - AstraZeneca adds novel systemic lupus erythematosus target with BenevolentAI
2024-06-25 05:10:44 ET
More on AstraZeneca, BenevolentAI S.A., etc.
- AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade)
- AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
- AstraZeneca: A Triple Shot Of Income, Growth, And Value
- AstraZeneca breast cancer therapy fails in late-stage trial
- AstraZeneca gets FDA okay for Imfinzi for endometrial cancer